EFPIA calls for new debate on drug pricing
This article was originally published in SRA
Executive Summary
The research-based pharmaceutical industry is looking at new ways to best characterise the “value for money” offered by their products following the spate of announcements by certain European Union member states of drug price cuts in response to the economic crisis1,2. Vibha Sharma reports from the press conference preceding the 2010 general meeting of European pharmaceutical industry association, EFPIA, held in London from 21-22 June.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.